Adoptive transfer of these transduced PBLs resulted in a significant reduction in tumor growth in a xenograft model by detecting human KRAS-mutant pancreatic cells.606 Currently, two phase I/II clinical trials using engineered TCRs are recruiting patients with cancer that has the KRASG12V or KRASG12D molecule on the surface of tumors, to determine if anti-KRASG12D mTCR- or anti-KRASG12V mTCR-transduced PBLs can mediate the regression of tumors harboring the corresponding RAS mutation (NCT03745326, NCT03190941). The gene discussed is KRAS; the disease is cancer.